Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and practical-use claims match the provided label excerpts (e.g., hepatic glucose production, insulin sensitivity, adjunct use with diet/exercise, lactic acidosis precautions, GI adverse reactions). However, many claims are either unsupported or go beyond the provided label excerpts (e.g., first-line status, hydrochloride meaning/formulation, IR/ER-specific comparative dosing claims, and several administration/titration statements not explicitly supported for ER).
Category Scores
Accurate Statements
Metformin reduces hepatic glucose production.
Clinical Pharmacology (Section 12): “Metformin decreases hepatic glucose production...”
Metformin improves insulin sensitivity.
Clinical Pharmacology (Section 12): “…improves insulin sensitivity…”
Common side effects of metformin include nausea.
Adverse Reactions: “Diarrhea and Nausea/Vomiting” reported in >5% and more common than placebo.
Common side effects of metformin include diarrhea.
Adverse Reactions: “Diarrhea” reported in >5% and more common than placebo.
Common side effects of metformin include abdominal discomfort.
Adverse Reactions: includes “abdominal pain” and other GI-related adverse reactions (e.g., constipation, distention abdomen, dyspepsia/heartburn).
Gastrointestinal side effects often improve when metformin is taken with meals.
Dosage & Administration indicates taking ER “once daily with the evening meal” and the excerpted label context supports gradual escalation and GI-related adverse reaction management via dosing/taking with meals. (No explicit statement: “often improve,” but this direction is aligned with provided administration and escalation excerpts.)
Clinicians pay special attention to situations that increase risk of serious complications, particularly in people with significant kidney impairment.
Warnings/Precautions: risk factors include renal impairment; contraindication for eGFR <30 and renal impairment precautions.
Dehydration increases risk of serious complications and may lead clinicians to adjust or temporarily stop metformin.
Warnings/Precautions excerpt lists risk factors for lactic acidosis including hypoxic states and mentions discontinuation if suspected lactic acidosis; however “dehydration” is not explicitly named in the provided excerpts, so support is indirect to the concept of risk factors.
Severe infection increases risk of serious complications and may lead clinicians to adjust or temporarily stop metformin.
Warnings/Precautions excerpt includes risk factors including hypoxic states and advises immediate discontinuation if lactic acidosis is suspected; infection is not explicitly named in provided excerpts, so support is indirect.
Clinicians may adjust or temporarily stop metformin in people undergoing certain procedures involving contrast dyes.
Dosage & Administration (Section 10): “Discontinue... at the time of, or prior to, an iodinated contrast imaging procedure. Re-evaluate eGFR 48 hours after...”
Metformin hydrochloride extended-release tablets, USP should generally be given once daily with the evening meal.
Dosage & Administration (Section 10): “should generally be given once daily with the evening meal...”
Metformin hydrochloride extended-release tablets must be swallowed whole and never crushed or chewed.
Dosage & Administration (Section 10): “must be swallowed whole and never crushed or chewed.”
Unsupported Statements
Metformin hydrochloride is used to treat type 2 diabetes.
The label excerpt provided is for ER tablets and states indication as adjunct to diet/exercise to improve glycemic control in patients with type 2 diabetes. The claim is broadly true to the disease context but is less precise than the provided label wording; not enough to score as fully supported.
Metformin hydrochloride is typically used as a first-line medication to help lower blood sugar.
No statement about “first-line medication” or typical prescribing hierarchy is present in the supplied label excerpts.
Metformin does not directly force the pancreas to release more insulin.
No such statement appears in the provided label excerpts.
For most practical purposes, metformin hydrochloride is metformin in a specific chemical form used in many tablet formulations.
No explicit label excerpt supports equivalence phrasing about “most practical purposes” or “specific chemical form” across formulations.
The active medicine is metformin.
Label excerpts provided refer to metformin hydrochloride as the drug substance; no excerpt explicitly states “active medicine is metformin” independent of hydrochloride.
“Hydrochloride” refers to how the drug is formulated.
No excerpt defines “hydrochloride” in this way.
Common metformin product types include immediate-release tablets.
The provided label excerpts are for ER tablets; they do not mention immediate-release products.
Common metformin product types include extended-release tablets.
The provided excerpts do cover ER tablets, but the claim about “common product types” is not explicitly stated.
If switching between immediate-release and extended-release metformin, the prescriber usually adjusts the dose.
No excerpt provided discusses switching between IR and ER or dose adjustment practices for that switch.
Patients generally take metformin with food to reduce common stomach side effects.
The label excerpt supports taking ER with the evening meal and gradual escalation, but does not explicitly state the purpose as “to reduce common stomach side effects” or “generally.”
Dosing of metformin often starts low.
Supported for ER by “started at a low dose,” but the claim is general “metformin” (not explicitly ER) and uses “often,” which is not in the excerpt.
Metformin doses are titrated upward based on blood glucose response and tolerability.
The label excerpt says “gradual dose escalation,” but “based on blood glucose response and tolerability” is not explicitly stated in provided excerpts.
Titration upward is especially noted with extended-release products.
Provided excerpt mentions gradual escalation for ER, but does not compare or state this is “especially” for ER.
Gastrointestinal side effects often improve when metformin is taken with meals.
Label excerpt supports taking with the evening meal and gradual escalation, but does not explicitly state “often improve.” (Mechanistically plausible, but not supported verbatim in provided text.)
In people with kidney disease, clinicians may adjust or temporarily stop metformin.
The label excerpt explicitly provides contraindication (eGFR <30), initiation not recommended for eGFR 30–45, and discontinuation if eGFR later falls below 30; it does not explicitly state “temporarily stop” for “kidney disease” generally.
Metformin is an old, widely available generic medicine.
No such statement appears in the provided label excerpts.
Patent and exclusivity details are more relevant to specific brand-name products or particular formulation/extended-release patents, not to “metformin hydrochloride” as a whole.
No such regulatory/patent-exclusivity discussion appears in the provided label excerpts.
Metformin product type (immediate-release vs extended-release) affects dosing schedules and how the medication is released and absorbed over time.
While the label excerpt provides ER-specific administration and PK information, it does not explicitly discuss IR vs ER differences in this way within provided excerpts.
Contradictions
Important Omissions
Key contraindications were not explicitly stated in the AI response set provided (e.g., eGFR <30 mL/min/1.73m2; known hypersensitivity; acute/chronic metabolic acidosis including DKA).
Importance:
Moderate
Boxed warning status was not addressed (if any) and lactic acidosis management specifics (immediate discontinuation and prompt hemodialysis when suspected) were not explicitly incorporated into the AI claims provided.
Importance:
Moderate
Drug interaction specifics from the label excerpt (e.g., topiramate/carbonic anhydrase inhibitors and alcohol warnings) were not clearly mapped to the specific AI claims list provided.
Importance:
Moderate
ER-specific administration instructions regarding swallowing whole and never crushing/chewing were not included among the claims listed (only GI/food-related statements were).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several dosing/administration and risk-management statements are partially supported or are generalized beyond the provided ER label excerpts (e.g., first-line status, switching IR↔ER guidance, and temporary stopping in kidney disease/infection/dehydration). Missing explicit contraindications and management steps could reduce label-alignment for safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are either unsupported or not precisely stated relative to the provided ER label excerpts, and several label-critical safety details (contraindications/management) are omitted or not explicitly tied to the ER labeling text.
Suggested Improvement
Restrict claims to statements explicitly present in the supplied ER label excerpts (Section 1, 4, 5/6, 7, 10, and 12). Replace generalized statements (e.g., “first-line,” IR↔ER switching, “active medicine is metformin,” “hydrochloride refers to formulation,” “temporary stop” in kidney disease/infection/dehydration) with label-anchored wording (adjunct to diet/exercise, ER administration with evening meal, gradual escalation, contraindications by eGFR <30, contrast procedure discontinuation/restart with 48-hour eGFR re-evaluation, and lactic acidosis immediate discontinuation with supportive care and prompt hemodialysis when suspected).